KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to -$141.6 million.

  • Halozyme Therapeutics' Net Income towards Common Stockholders fell 20334.2% to -$141.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $316.9 million, marking a year-over-year decrease of 2864.82%. This contributed to the annual value of $316.9 million for FY2025, which is 2864.32% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Net Income towards Common Stockholders of -$141.6 million as of Q4 2025, which was down 20334.2% from $175.2 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' Net Income towards Common Stockholders peaked at $216.6 million during Q3 2021, and registered a low of -$141.6 million during Q4 2025.
  • In the last 5 years, Halozyme Therapeutics' Net Income towards Common Stockholders had a median value of $79.3 million in 2023 and averaged $82.4 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 55707.03% in 2021, then tumbled by 20334.2% in 2025.
  • Halozyme Therapeutics' Net Income towards Common Stockholders (Quarter) stood at $66.8 million in 2021, then decreased by 13.58% to $57.7 million in 2022, then soared by 47.98% to $85.4 million in 2023, then soared by 60.46% to $137.0 million in 2024, then tumbled by 203.34% to -$141.6 million in 2025.
  • Its Net Income towards Common Stockholders was -$141.6 million in Q4 2025, compared to $175.2 million in Q3 2025 and $165.1 million in Q2 2025.